EU panel recommends authorization of GSK diabetes drug


A European Medicines Agency committee has recommended that the EU approve GlaxoSmithKline's (GSK) once-weekly Albiglutide drug for Type 2 diabetes.

The treatment belongs to the same class of GLP-1 therapies as Novo Nordisk's (NVO) Victoza, and Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca (AZN).

The European Commission usually follows the recommendations of the EMA. GSK expects a decision in Q1. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs